The state of Georgia currently has 16 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Atlanta, Augusta, Decatur and Savannah.
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
Recruiting
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.
Gender:
All
Ages:
50 years and above
Trial Updated:
02/20/2024
Locations: Clinical Research Atlanta, Stockbridge, Georgia
Conditions: Influenza, Human, SARS-CoV-2 Infection, COVID-19
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
Recruiting
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. Participants will self-report any new or worsening symptoms or medical events experienced while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a partic... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
02/12/2024
Locations: Morehouse School of Medicine, Atlanta, Georgia +8 locations
Conditions: Covid19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Recruiting
The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to separate vaccines for the protection against influenza and SARS-CoV-2. Influenza and COVID-19 are diseases that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. Giving both influenza and COVID-19 vaccines together against influenza and SARS-CoV-2 could provide great benefits to both patients and ca... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
02/06/2024
Locations: Synexus Clinical Research US, Inc., Atlanta, Georgia +5 locations
Conditions: Influenza, COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Emory University, Atlanta, Georgia
Conditions: COVID-19
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Recruiting
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific cli... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Emory Johns Creek Hospital, Atlanta, Georgia +1 locations
Conditions: Infectious Pneumonia, Severe COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Recruiting
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Atea Study Site, Eatonton, Georgia
Conditions: SARS CoV 2 Infection, COVID-19
Promoting Engagement and COVID-19 Testing for Health
Recruiting
PEACH2 is a community-based study, targeting individuals affected by diabetes. Study participants will be randomized into the PEACH2 Intervention Arm or the Control Arm. The intervention lasts for 16 weeks and participants will be followed for 12 months in total.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Emory University, Atlanta, Georgia
Conditions: COVID-19
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
Recruiting
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Gender:
All
Ages:
40 years and above
Trial Updated:
01/08/2024
Locations: 341 - Lifeline Primary Care / CCT Research, Lilburn, Georgia
Conditions: COVID-19
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. Substudy A design: Phase 1 includes participant... Read More
Gender:
All
Ages:
Between 6 months and 11 years
Trial Updated:
12/18/2023
Locations: Emory University School of Medicine, Atlanta, Georgia +4 locations
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Arginine Replacement Therapy in COVID-19
Recruiting
The purpose of this study is to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed in Children's Healthcare of Atlanta, Egleston campus. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
11/18/2023
Locations: Children's Healthcare of Atlanta (CHOA), Egleston, Atlanta, Georgia
Conditions: COVID-19
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
Recruiting
An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have =<2500 U/mL SARS-CoV-2 S antibody concentration using the Roche Elecsys(R) anti-RBD assay. Up to 80 participants will be enrolled in this study. Eligible participants will receive a dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine candidate.. The primary objective is to determine whether a bo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/21/2023
Locations: Emory University School of Medicine: Transplantation, Atlanta, Georgia
Conditions: COVID-19, Kidney Transplant
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/01/2023
Locations: Augusta University, Augusta, Georgia
Conditions: Community-acquired Pneumonia, Influenza, COVID-19